Table 3_Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients.docx by Roberta Belli (6939221)

“…Finally, treatment with anti-IL-23 led to a reduction in visfatin levels in female psoriatic patients and resulted in a significant decrease in fat mass percentage in men. …”

Image 1_Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients.jpg by Roberta Belli (6939221)

“…Finally, treatment with anti-IL-23 led to a reduction in visfatin levels in female psoriatic patients and resulted in a significant decrease in fat mass percentage in men. …”

Data Sheet 1_Global, regional, and national disease burden of tobacco-related Alzheimer’s disease among individuals over the age of 55: a global burden of disease study.docx by Tianyi Dong (8060000)

“…It is anticipated that the burden will continue to gradually decrease from 2021 to 2040.</p>Conclusion<p>Although the global burden of tobacco-related Alzheimer’s disease among the older adults declined from 1990 to 2021, significant disparities existed across regions, age groups, sex, and SDI.…”

Data Sheet 1_Perceived protective behavioral changes in Chinese residents post-dynamic zero-COVID policy lifting: a cross-sectional study.docx by Yuan-Yuan Song (6287387)

“…Avoiding dining out or gathering with friends had the highest percentage of individuals reporting an increase (71.3%), whereas maintaining a social distance of more than 1 m had the highest percentage of individuals reporting a decrease (17.5%). …”

Table 7_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 2_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 3_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 4_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xls by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 1_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 6_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 5_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.docx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 1_A national population-based study of mortality and risk factors in COVID-19-hospitalized patients in Spain (2020–2021).docx by José-Manuel Ramos-Rincón (10428656)

“…IHM rose with age, from 0.8% in patients aged 18–39 to 31.7% in those ≥80 years (p < 0.001), but significant decreases were observed across all age groups after vaccination, especially in those ≥80 years (AOR: 0.76, 95% CI: 0.75–0.79, p < 0.001). …”

Table 1_Impact of comorbid burden on global left cardiac function and prediction models for myocardial function damage: a cardiac magnetic resonance feature-tracking study.docx by XiaoFeng Qu (20718092)

“…</p>Conclusion<p>CMR-FT can detect left-sided myocardial function damage in patients with comorbid burden but without organic heart disease prior to a decrease in LVEF. Comorbid burden combined with male sex, PBG, and FBG showed excellent predictive ability for LV myocardial function damage. …”

<b>Data used for analyses in the manuscript 'Sleep Regularity and Duration are Associated with Depression Severity in a Nationally Representative United States Sample'</b> by Katherine Maki (7445153)

“…Sex was an additional independent predictor, with females exhibiting higher depression scores, and a significant sex × SRI interaction revealed that the inverse relationship between SRI and depressive symptoms was stronger in females than in males. …”

<b>Data from: </b><b>Experimentally increased food availability allows for earlier departure in a long-distance migratory shorebird</b> by Thomas Lameris (20888213)

“…We only included detections that showed a typical pattern of a ‘departure event’, with a peak in signal strength followed by a gradual decrease in signal strength (Müller <i>et al.…”

Image 1_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 2_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 5_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 6_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”